+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genomics - Global Strategic Business Report

  • PDF Icon

    Report

  • 422 Pages
  • June 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 4805048
The global market for Genomics was estimated at US$45.7 Billion in 2025 and is projected to reach US$117.3 Billion by 2032, growing at a CAGR of 14.4% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Genomics Market - Key Trends and Drivers Summarized

Why Is Genomics Revolutionizing Healthcare, Agriculture, and Biotechnology?

Genomics, the study of an organism's complete set of DNA, including all of its genes, is transforming industries like healthcare, agriculture, and biotechnology. But why is genomics so revolutionary in today's landscape? Genomics provides a deep understanding of genetic blueprints, enabling scientists and healthcare providers to predict, diagnose, and treat diseases more effectively, while also enhancing agricultural productivity and driving biotechnological innovations. By analyzing genomes, researchers can identify mutations, gene functions, and interactions that are crucial for personalized medicine, disease prevention, and the development of new therapeutics.

In healthcare, genomics allows for personalized medicine - tailoring treatments to a patient’s genetic profile, which improves efficacy and reduces adverse effects. It is used to identify genetic predispositions to diseases such as cancer, diabetes, and heart disease, enabling early detection and targeted interventions. In agriculture, genomics is enhancing crop yields, pest resistance, and nutritional value by enabling precise genetic modifications. Farmers can now grow crops that are more resilient to climate change, disease, and other stressors. In biotechnology, genomics is fundamental to synthetic biology, where genetic sequences are designed to create new biological systems, such as biofuels, pharmaceuticals, and industrial enzymes. With its vast potential to reshape industries, genomics is at the cutting edge of scientific discovery and innovation, making it one of the most impactful fields in the modern era.

How Are Technological Advancements Driving Progress in Genomics?

Technological advancements are dramatically accelerating progress in genomics, making genome sequencing faster, more affordable, and more accessible. One of the most transformative technologies in this space is next-generation sequencing (NGS), which allows for the rapid sequencing of entire genomes at a fraction of the cost and time required by earlier methods like Sanger sequencing. NGS has democratized genomic research by making it feasible for labs of all sizes to sequence genomes and analyze genetic data in large volumes. This technology has paved the way for projects like the Human Genome Project, which mapped the entire human genome and has since become a foundation for countless advances in genomics.

Another significant technological advancement is in bioinformatics - the use of computational tools to manage and analyze vast amounts of genomic data. As genome sequencing produces enormous datasets, bioinformatics platforms are essential for making sense of the information. Artificial intelligence (AI) and machine learning algorithms are being applied to identify patterns, detect mutations, and predict how specific genetic variations affect health outcomes. These tools are making genomics more precise by allowing scientists to connect genetic data with clinical insights, leading to breakthroughs in personalized medicine and disease research.

Moreover, advances in gene-editing technologies such as CRISPR-Cas9 are allowing for the precise manipulation of genetic sequences. CRISPR has revolutionized how scientists approach genetic research by making it easier to edit genes, leading to discoveries about gene function and the development of new gene therapies. This technology is also advancing agricultural genomics, where scientists can edit crops to enhance traits such as drought tolerance, pest resistance, and nutritional value. As technologies like NGS, bioinformatics, and CRISPR evolve, genomics is becoming more efficient, scalable, and capable of addressing complex biological questions across various industries.

Why Is Genomics Critical for Advancing Personalized Medicine and Disease Prevention?

Genomics is essential for advancing personalized medicine and improving disease prevention because it enables a deeper understanding of the genetic factors that contribute to health and disease. By analyzing a person’s genome, healthcare providers can identify specific genetic mutations that may predispose them to conditions like cancer, heart disease, or neurological disorders. This level of insight allows for early detection and targeted interventions that can prevent the onset of disease or tailor treatments to individual patients. For example, in oncology, genomics is used to profile the genetic mutations in a tumor, allowing oncologists to select therapies that specifically target those mutations, improving treatment efficacy and minimizing side effects.

In disease prevention, genomics is playing an increasingly important role in identifying individuals who are at risk of developing genetic disorders. For instance, genomic screening can identify carriers of inherited conditions like cystic fibrosis or sickle cell anemia, enabling early intervention or informed reproductive decisions. In cardiology, genomics can help detect mutations that lead to conditions like hypertrophic cardiomyopathy or arrhythmias, allowing for preventive measures such as lifestyle changes, regular monitoring, or even surgical interventions to mitigate risks. This proactive approach to healthcare helps individuals avoid severe health complications and improves long-term outcomes.

Genomics also underpins pharmacogenomics, the study of how genes influence an individual’s response to medications. By understanding genetic variations that affect drug metabolism, healthcare providers can prescribe medications that are more effective for a particular genetic makeup, reducing the risk of adverse drug reactions and improving treatment success. For patients undergoing cancer treatment, pharmacogenomics can identify the drugs most likely to work based on their tumor’s genetic profile, while minimizing harmful side effects. This precision medicine approach ensures that treatments are more personalized and effective, marking a shift from one-size-fits-all healthcare to a more tailored strategy that considers each patient’s unique genetic blueprint.

By improving diagnostic accuracy, enabling early detection, and personalizing treatment plans, genomics is revolutionizing healthcare and disease prevention. This shift toward individualized care is resulting in better patient outcomes and more efficient use of medical resources, highlighting the critical role genomics plays in the future of healthcare.

What Factors Are Driving the Growth of the Genomics Market?

Several key factors are driving the rapid growth of the genomics market, including technological advancements, increasing demand for personalized medicine, rising government funding, and expanding applications in agriculture and biotechnology. First, technological innovations like next-generation sequencing (NGS) have made genome sequencing faster, cheaper, and more accessible. The significant drop in sequencing costs has allowed more research institutions, hospitals, and biotech companies to adopt genomic technologies, fueling growth across industries. NGS, coupled with improvements in bioinformatics and AI-driven data analysis, is allowing scientists to make sense of massive amounts of genetic data, further accelerating the expansion of genomics applications.

Second, the growing demand for personalized medicine is a major driver of the genomics market. As healthcare shifts toward more individualized treatment approaches, the ability to tailor medical interventions based on a patient’s genetic profile is becoming increasingly important. Genomics enables healthcare providers to diagnose genetic disorders more accurately, identify at-risk individuals, and develop personalized treatment plans that improve outcomes. With chronic diseases and cancer on the rise, the need for genomics-based diagnostics and therapies is expanding, driving significant growth in clinical genomics applications.

Third, governments and public health organizations are increasing their investments in genomics research and healthcare initiatives. Projects like the 100,000 Genomes Project in the UK and the Cancer Moonshot Initiative in the US are aimed at accelerating discoveries in genomics to improve public health and treat diseases more effectively. Such large-scale genomic studies are generating valuable data that are driving advancements in precision medicine, drug discovery, and population health management. Increased government funding is also enabling the establishment of national genomic databases, which can be used to identify population-level health trends and facilitate the development of new treatments and prevention strategies.

Moreover, the expanding applications of genomics in agriculture and biotechnology are contributing to market growth. In agriculture, genomics is being used to develop crops with enhanced traits, such as improved yield, pest resistance, and tolerance to environmental stresses like drought or heat. Genomic tools are also helping farmers breed livestock with better health, productivity, and disease resistance. In biotechnology, genomics is driving innovation in drug development, biofuels, and industrial enzymes by enabling the design of organisms with specific, engineered genetic traits. These applications are not only improving food security and agricultural sustainability but also driving commercial demand for genomics technologies.

Finally, public awareness of the benefits of genomics is growing, particularly through direct-to-consumer (DTC) genetic testing services. Companies like 23andMe and AncestryDNA are making genetic information more accessible to the general public, allowing individuals to learn about their ancestry, health risks, and genetic traits. This increasing public engagement with genomics is contributing to market growth as consumers seek more information about their genetics and related healthcare options.

In summary, the genomics market is experiencing robust growth due to technological advancements like NGS, increasing demand for personalized medicine, government funding, and expanding applications in agriculture and biotechnology. As the cost of genomic technologies continues to decrease and their capabilities expand, the genomics market is poised to play an even more central role in advancing healthcare, agriculture, and scientific research.

Report Scope

The report analyzes the Genomics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product and Services (Consumables, Systems & Software, Services); Technology (Sequencing, PCR, Nucleic Acid Extraction & Purification, Other Technologies).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Products Component segment, which is expected to reach US$83.4 Billion by 2032 with a CAGR of 16.0%. The Services Component segment is also set to grow at 11.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $13.4 Billion in 2025, and China, forecasted to grow at an impressive 13.7% CAGR to reach $20.2 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Genomics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Genomics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Genomics Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Agilent Technologies, Inc., BGI Europe, Bio-Rad Laboratories, Inc., Danaher Corporation, Ennostar Corporation and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Genomics market report include:

  • Agilent Technologies, Inc.
  • BGI Europe
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Ennostar Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Illumina, Inc.
  • Oxford Nanopore Technologies Plc
  • Pacific Biosciences of California, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 2,719 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Genomics - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Surging Demand for Genomic Data in Healthcare Personalization
  • Technological Advancements in High-Throughput Sequencing Technologies
  • Expansion of Consumer Genomics and Direct-to-Consumer Testing Services
  • Integration of Artificial Intelligence in Genomic Data Analysis
  • Rising Use of Genomics in Rare Disease Diagnosis and Oncology
  • Market Opportunities in Prenatal and Newborn Genetic Screening
  • Role of Genomics in Drug Discovery and Development
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Genomics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Products Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Products Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Products Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Functional Genomics Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Functional Genomics Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Functional Genomics Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Biomarker Discovery Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Biomarker Discovery Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Biomarker Discovery Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Pathway Analysis Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Pathway Analysis Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Pathway Analysis Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Epigenomics Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Epigenomics Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Epigenomics Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Other Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Other Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Other Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Agriculture & Animal Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Agriculture & Animal Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Agriculture & Animal Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Genomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
REST OF WORLD
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies, Inc.
  • BGI Europe
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Ennostar Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Illumina, Inc.
  • Oxford Nanopore Technologies Plc
  • Pacific Biosciences of California, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.

Table Information